ACS Medicinal Chemistry Letters · 2011 · 48 citations · 6 references
MedicineMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryMolecular PharmacologyChemokine NetworksChemokine SignalingDrug-receptor InteractionsLigand BindingReceptor PharmacologyReceptor-ligand InteractionsCellular ChemotaxisChemokine Receptor AntagonismChemotaxisFree FractionG Protein-coupled Chemokine ReceptorsG-protein-coupled ReceptorsMonocyte Chemoattractant Protein-1Selectivity
We report the identification of 13 (INCB3284) as a potent human CCR2 (hCCR2) antagonist. INCB3284 exhibited an IC50 of 3.7 nM in antagonism of monocyte chemoattractant protein-1 binding to hCCR2, an IC50 of 4.7 nM in antagonism of chemotaxis activity, an IC50 of 84 μM in inhibition of the hERG potassium current, a free fraction of 58% in protein binding, high selectivity over other chemokine receptors and G-protein-coupled receptors, and acceptable oral bioavailability in rodents and primates. In human clinical trials, INCB3284 exhibited a pharmacokinetic profile suitable for once-a-day dosing (T 1/2 = 15 h).
6
Identification of a sulfonamide series of CCR2 antagonists
Simon Peace, Joanne Philp, Carl Brooks et al. · Bioorganic & Medicinal Chemistry Letters · 2010 · 35 citations · Full text